CTOs on the Move

Phathom Pharmaceuticals

www.phathompharma.com

 
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Phathom Pharmaceuticals raised $50M on 05/15/2019
Phathom Pharmaceuticals raised $90M on 05/15/2019

Similar Companies

Fluid Air

Fluid Air is a Aurora, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GPX Update

Fluidx Medical Technologys novel GPX Embolic Device is a durable embolic that is easy to use, controllable, and effective for vessel occlusion.

Mixlab

Mixlab is a modern veterinary pharmacy that specializes in pharmaceutical manufacturing and compounding for veterinary use.

The Pharmacy Examination Board of Canada

The Pharmacy Examination Board of Canada is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Envivo

Envivo is a Watertown, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.